Table 3. Summary of statistical analysis testing if GBS and GBS-related AEs occur independently of vaccine type.
year | #GBS and GBS-related AEs(TIV) | total cases reported in that year (TIV) | # GBS and GBS-related AEs(LAIV) | total cases reported in that year (LAIV) | P-Val (selected AEs occur independently of TIV) |
2003 | 150 | 1790 | 0 | 34 | 7.81E-02 |
2004 | 163 | 2187 | 9 | 339 | 1.10E-03 |
2005 | 278 | 2842 | 13 | 198 | 1.37E-01 |
2006 | 244 | 2430 | 12 | 172 | 1.92E-01 |
2007 | 292 | 3165 | 2 | 180 | 1.84E-04 |
2008 | 321 | 3725 | 14 | 660 | 7.01E-09 |
2009 | 498 | 5231 | 36 | 1272 | 6.46E-15 |
2010 | 625 | 7165 | 26 | 797 | 9.44E-08 |
2011 | 134 | 1021 | 0 | 75 | 8.12E-04 |
Note: GBS-related muscle and neurological AEs studied here included musculoskeletal pain, paraesthesia, and muscular weakness.